All In Biotech

Drug Trial Radar · NCT01797445

Study to Evaluate the Safety and Efficacy of E/C/F/TAF Versus E/C/F/TDF in HIV-1 Positive, Antiretroviral Treatment-Naive Adults

A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults

Last checked: Nov 19, 2026Latest source record: Mar 2, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 872 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

872

Actual

Start

Mar 12, 2013

Primary completion

Sep 19, 2014

Study completion Oct 3, 2018

Sponsor

Lead sponsor
Gilead SciencesGilead Sciences (GILD)
Sponsor type
Industry
First posted
Feb 22, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to evaluate the efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) fixed-dose combination (FDC) versus elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (E/C/F/TDF) in HIV-1 positive, antiretroviral treatment-naive adults.

Conditions

  • HIV
  • HIV Infections

Interventions

  • E/C/F/TAFDrug

    150/150/200/10 mg FDC tablet administered orally once daily

  • E/C/F/TDFDrug

    150/150/200/300 mg FDC tablet administered orally once daily

  • E/C/F/TDF PlaceboDrug

    Tablet administered orally once daily

  • E/C/F/TAF PlaceboDrug

    Tablet administered orally once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Achieving HIV-1 RNA < 50 Copies/mL at Week 48Time frame: Week 48

Locations

117 sites in 11 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • Spectrum Medical Group

    Phoenix, Arizona

  • Kaiser Permanente - Los Angeles Medical Center

    Los Angeles, California

  • University of Southern California AIDS Clinical Trials Group

    Los Angeles, California

  • Peter J. Ruane, Inc.

    Los Angeles, California

  • Anthony Mills MD Inc

    Los Angeles, California

  • Alameda County Medical Center

    Oakland, California

  • Stanford University

    Palo Alto, California

  • University of California, Davis Medical Center

    Sacramento, California

  • Kaiser Permanente Medical Group

    Sacramento, California

  • La Playa Medical Group and Clinical Research

    San Diego, California

  • Kaiser Permanente San Francisco

    San Francisco, California

  • Kaiser Permanente

    San Leandro, California

  • Los Angeles Biomedical Research Institute at Harbor - UCLA Medical Center

    Torrance, California

  • University of Colorado

    Aurora, Colorado

  • APEX Research LLC

    Denver, Colorado

  • Greenwich Hospital

    Greenwich, Connecticut

  • Yale University

    New Haven, Connecticut

  • Dupont Circle Physicians Group

    Washington D.C., District of Columbia

  • Whitman-Walker Health

    Washington D.C., District of Columbia

  • Capital Medical Associates, PC

    Washington D.C., District of Columbia

  • Medical Faculty Associates

    Washington D.C., District of Columbia

  • Gary J. Richmond,M.D.,P.A.

    Fort Lauderdale, Florida

  • Midway Immunology and Research Center

    Ft. Pierce, Florida

  • AIDS Healthcare Foundation

    Miami, Florida

  • AIDS Healthcare Foundation

    Miami Beach, Florida

  • Orlando Immunology Center

    Orlando, Florida

  • Idocf/Valuhealthmd

    Orlando, Florida

  • Infectious Diseases Associates of NW FL

    Sarasota, Florida

  • University of South Florida

    Tampa, Florida

  • Infectious Disease Research Institute Inc.

    Tampa, Florida

  • St. Joseph's Comprehensive Research Institute

    Tampa, Florida

  • Triple O Research Institute PA

    West Palm Beach, Florida

  • AIDS Research Consortium of Atlanta

    Atlanta, Georgia

  • Atlanta ID Group, PC

    Atlanta, Georgia

  • Emory University

    Atlanta, Georgia

  • Georgia Regents University

    Augusta, Georgia

  • Infectious Disease Specialist of Atlanta

    Decatur, Georgia

  • Mercer University

    Macon, Georgia

  • University of Hawaii - Hawaii Center for AIDS

    Honolulu, Hawaii

Showing 40 of 117 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.